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Abstract
Mutations in PfCRT (Plasmodium falciparum chloroquine-resistant transporter), particularly the substitution at amino acid
position 76, confer chloroquine (CQ) resistance in P. falciparum. Point mutations in the homolog of the mammalian
multidrug resistance gene (pfmdr1) can also modulate the levels of CQ response. Moreover, parasites with the same pfcrt
and pfmdr1 alleles exhibit a wide range of drug sensitivity, suggesting that additional genes contribute to levels of CQ
resistance (CQR). Reemergence of CQ sensitive parasites after cessation of CQ use indicates that changes in PfCRT are
deleterious to the parasite. Some CQR parasites, however, persist in the field and grow well in culture, which may reflect
adaptive changes in the parasite genome to compensate for the mutations in PfCRT. Using three isogenic clones that have
different drug resistance profiles corresponding to unique mutations in the pfcrt gene (106/1
K76, 106/1
76I, and 106/
76I-352K),
we investigated changes in gene expression in these parasites grown with and without CQ. We also conducted
hybridizations of genomic DNA to identify copy number (CN) changes in parasite genes. RNA transcript levels from 45 genes
were significantly altered in one or both mutants relative to the parent line, 106/1
K76. Most of the up-regulated genes are
involved in invasion, cell growth and development, signal transduction, and transport activities. Of particular interest are
genes encoding proteins involved in transport and/or regulation of cytoplasmic or compartmental pH such as the V-type H
+
pumping pyrophosphatase 2 (PfVP2), Ca
2+/H
+ antiporter VCX1, a putative drug transporter and CN changes in pfmdr1.
These changes may represent adaptations to altered functionality of PfCRT, a predicted member of drug/metabolite
transporter superfamily found on the parasite food vacuole (FV) membrane. Further investigation of these genes may shed
light on how the parasite compensates for functional changes accompanying drug resistance mutations in a gene coding
for a membrane/drug transporter.
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Introduction
The identification of pfcrt as the key gene associated with
chloroquine resistance (CQR) [1,2] is one of the most important
advances in our understanding of antimalarial drug resistance.
Polymorphisms in the pfcrt gene were demonstrated to confer CQR
using both drug selection and genetic transformation [1,3,4,5,6]. A
lysine to threonine substitution at position 76 (K76T) hasbeen found
in every in vitro-tested CQR parasite from worldwide surveys of field
isolates [7,8]. However, the molecular mechanism of the PfCRT
effect on parasite susceptibility to CQ remains controversial [9].
Furthermore, the endogenous role of PfCRT in the malaria parasite
is not known. An understanding of the natural functions of PfCRT
and other genes in the same cellular processes will provide a clearer
picture of drug resistance evolution in the malaria parasite [10].
PfCRT is a 48 kDa protein with 10 predicted transmembrane-
spanning domains and is located on the food vacuole (FV)
membrane of intraerythrocytic stage parasites [1,3]. Bioinformatic
analysis suggested that PfCRT belongs to the drug-metabolite
transporter (DMT) superfamily [11].
An unanswered question is whether the resistant pfcrt haplotype
alone can generate a viable CQR parasite. Mutations conferring
drug resistance often have deleterious effects on an organism
[12,13]. Recent studies suggest that nucleotide substitutions in pfcrt
may inflict some costs on parasite survival because discontinuation
of CQ is sometimes followed by a slow reemergence of CQS
parasites in the field [14,15]. Conversely, some CQR parasites
(e.g. the FCB and Dd2 lines) appear to be well adapted to growth
in vitro even in the absence of drug pressure, suggesting potential
compensatory or adaptive mutations that can overcome the
deleterious changes in drug resistant genes. Compensatory
mutations typically occur under drug selection to minimize the
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resulting balanced genome minimizes the genetic burden of
resistance [16]. The intense selection by CQ on P. falciparum has
likely led to a cohort of alleles that may modulate the level of
resistance and stabilize basic biological function of the cell. These
additional mutations can be embedded in the same pathways and
cellular processes as the gene conferring drug resistance or more
changes in the same gene and may indirectly modulate the
response level to the selecting drug.
pfmdr1 has long been a focus of interest as a possible CQR gene,
yet it remains unclear what role it plays in CQR [17]. One
argument is that pfmdr1 plays a compensatory role in CQR [18]
while modulating responses to various drugs through indirect
physiologic roles dependent on point mutations and copy numbers
(CN) [19,20,21]. Because pfmdr1 influences parasite responses to
drugs with diverse structures and various modes of action, a non-
specific mechanism may be invoked through changes in FV
physiology. This hypothesis is supported by strong linkage
disequilibrium between variants in pfcrt and pfmdr1 [22,23],
perhaps involving a functional interplay between these proteins.
Different clonal CQR parasite lines display a wide range of CQ
IC50 values, indicative of incremental and additive effects on drug
phenotypes even when the pfcrt and pfmdr1 alleles are the same
[23,24]. The quantitative CQ response among the resistant
isolates range from values 2.5 to 200-fold higher than their
sensitive counterparts, even when pfcrt and pfmdr1 are unchanged,
indicating that the level of CQ response is influenced by additional
genes [19,23,25].
CQR parasites have spread from as few as five origins to their
current nearly global distribution, drastically altering the genomic
landscape of malaria parasites [8]. While much effort has focused
on understanding how key mutations in PfCRT produce CQR,
strikingly little is known about the genetic background of CQR,
the natural function of PfCRT and its molecular partners in the
basic biology of the parasite.
Microarrays can be used to detect transcriptional changes on a
genome basis and structural variation on the parasite chromo-
somes [26,27,28]. Studies have found that gene expression often
evolves more rapidly than do coding regions of these genes [29].
These changes in gene expression can provide insights into the
impact of acquired mutations, both random and adaptive, on
transcription and drug resistance. To study parasite responses to
mutations in pfcrt and the effects of these changes on parasite
survival, we compared the genome-wide gene expressional profiles
between two pfcrt mutant parasites derived by single-step drug
selection from a CQS parasite line, 106/1
K76 [3,5]. We evaluated
parasite gene expression in the presence and absence of sub-lethal
CQ pressure and identified various genes with altered expression
patterns, including those involved in growth, invasion and
transport activities in the context of newly selected point mutations
in PfCRT. We show that mutant parasites underwent simulta-
neous changes at multiple loci, including CN of pfmdr1.
Result
Global Gene Expression Profiles
To investigate parasite responses to mutations in the pfcrt gene,
we hybridized total RNA extracted from parasites with different
substitutions in the pfcrt gene. Raw data from 18 (six independent
biological replicates for each parasite clone) array chips showed
comparable data scales, distributions, and good RNA qualities
with no apparent RNA degradation in any hybridizations (Figure
S1, S2, and S3) [30]. The raw data were normalized to have the
same quantile distributions; and genes with coefficient of variance
(CV) $30% were filtered out. After normalization and processing,
3,356 (62%) reliable probe sets were retained for further analyses.
To further evaluate the quality of our data and compare
genome-wide gene expression profiles, we clustered all the 18
normalized microarray data sets using hierarchical clustering
analysis (HCA). HCA showed that the majority of the 3,356 genes
were not differentially expressed among all parasites (Figure 1) and
that six replicates of each parasite had similar expression pattern.
Additionally, 106/1
76I and 106/1
76I-352K showed similar up- and
down-patterns and were clustered closer to each other than to
their parent, 106/1
K76. Each replicate of the same parasite line,
Figure 1. Hierarchal clustering of 3,356 filtered probesets for 18 samples/replicates. Each horizontal bar represents a sample or replicate;
and each vertical line represents a probeset. Samples labeled in red are mRNA samples from 106/1
K76; cyan are from 106/1
76I; and yellow are from
106/1
76I-352K. Replicates 1–3 were samples from parasites without CQ treatment; and 4–6 were those treated with CQ for 3 h. Gene expression levels
were color-coded (color bar) from dark blue (log2 20.01) to red (log2 5).
doi:10.1371/journal.pone.0002484.g001
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than to those from other parasites, indicating no significant CQ
effect on global gene expression profiles.
Principle component analysis (PCA) on the whole genome
expression data showed that the first two principal components (or
two ‘‘super genes’’ derived from linear combination of expression
data from of 3,356 genes) account for 82.8% and 7.7% of the
variance in the data sets, respectively. Based on the first two
components, there were three distinguished clusters consisting of
six replicates from each parasite (Figure S4). The results suggested
that these two components could be potentially used to find gene
signatures or even used as signatures themselves to distinguish
these parasites, similar to those observed in HCA. However, genes
expressed at very low levels and with little variation among
different treatments, although biologically important, could be
missed in these analyses.
Differentially Expressed Genes in the Mutant Parasites
Genes with 2-fold up- or down-regulation plus a false discovery
rate (FDR) ,0.001 were defined as significantly differentially
expressed genes. Among the non-CQ treated parasites, when
compared with the parental line 106/1
K76, only 45 genes
significantly changed expression in one or both mutant parasites
that passed the stringent threshold (Table 1). Among the 34 up-
regulated genes, 10 genes encoded proteins of unknown function.
For the genes with putative functional assignment, genes encoding
proteins associated with parasite invasion such as rhoptry proteins
(4), merozoite membrane proteins (2), and apical membrane
antigen (1) topped the list in both mutant parasites. In addition, 10
genes involved in parasite growth and cell cycle regulation,
including two cysteine proteases (PFB0340c and PFB0345c), were
also up-regulated.
There were 11 genes that were significantly down-regulated or
not expressed/deleted in one or both mutants (Table 2). Of
interest, four of the genes (PF10_0016, PF10_0019, PF10_0020,
and PF10_0021) reside within a ,49 kb segment, including 3
contiguous genes at one end of chromosome 10, suggesting a
chromosomal deletion. Two of the genes (PF10_0015 and
PF10_0016) encode putative lipid transporters. The deleted genes
were confirmed using real time PCR (data not shown) and DNA
hybridization (see below).
Among the differentially expressed genes in the mutant
parasites, at least six genes encode putative transporters
(Table 1), three of which were involved in transporting Ca
2+/H
+
(PFF0170w), drug/metabolite (PFE0785c) and lipid (PF11_0370),
respectively. For the down-regulated/deleted transporter genes,
one was a putative amino acid transporter and two were lipid
transporters. Relative to the 106/1
K76 parasite, pfcrt was expressed
1.5-fold lower in both mutants; however, pfmdr1 was 2-fold lower
only in 106/1
76I (pfmdr1 was not listed in Table 1 because it did not
pass the FDR ,0.001 test). As pfcrt is also a putative drug/
metabolite transporter, changes in expression of various trans-
porting molecules was probably not random, suggesting that
mutations in PfCRT might disturb parasite transporting activities;
and the parasites responded by altering expression of various
transporters, particularly those transporting H
+ and lipids. Of
particular interest was the gene PFE0785c, as pfcrt was predicted to
encode a drug/metabolite transporter too [11,31].
In general, the patterns for both up- and down- regulated genes
in the two mutant parasites were mostly co-linear or parallel
(Table 1). However, for the up-regulated genes, the changes in
gene expression in 106/1
76I-352K were generally greater than those
in 106/1
76I. The higher (or lower) levels of up- or down regulation
of the genes could reflect parasite responses to additional change at
PfCRT 352K and/or QN selection pressure.
Expressional Changes under CQ Treatment
We also compared gene expression among the three parasites
exposed to low dose (half dose of parasite IC50, see methods) CQ
treatment for 3 h. We used the low drug concentrations because
we sought evidence of a physiological response rather than the
outright killing of parasites. Comparing gene expression of the
same parasite with or without CQ treatments, no genes with
significant changes (2 fold changes and FDR ,0.001) in
expression were found among all three parasites (two-way
ANOVA) or between each parasite pair (t-test). HCA and PCA
analyses clustered the samples from the same parasites with and
without CQ treatments together, indicating minimum CQ effects
on gene expression (Figure 1). We compared gene expression of
the mutants with that of 106/1
K76 after CQ treatment, and found
11 genes that significantly changed in the expression in one or
both mutants, eight of which also changed expression without CQ
treatment (Table 1 and 2). Of great interest was the 4 and 10 fold
up-regulation of a gene encoding the vacuolar type H
+ pumping
pyrophosphatase 2 (PfVP2, PFL1700c) that belongs to a novel
class of H
+ pump molecules found in plants and many protozoa
[32]. This protein could play a role in maintaining FV pH balance
and in compensating mutations in PfCRT. Further investigation of
the role of this gene and the gene encoding Ca
2+/H
+ antiporter in
maintaining pH in the parasite and in CQR may lead to a better
understanding of CQR and the biological functions of PfCRT.
Functional Enrichment Analysis of Gene Ontology (GO)
Biological Processes
Two-folddifferentlyexpressedgenesfrommutantsexposedtoCQ
treatment were further analyzed for their biological pathways (GO
terms). CQ-treated samples are highly enriched in glycerol and
polyol metabolic processes in both mutant parasites (Figure 2).
Enrichment of iron/cation transport activities was also found in the
106/1
76I-352K parasite, suggesting that CQ treatment could interfere
with many relevant ion channels. These included genes encoding
PfVP2, Ca
2+/H
+ antiporter, vacuolar ATP synthase (PF11_0412),
and P-type ATPase (PFC0840w), although the last two genes did not
pass our stringent criteria for selecting significantly differentially
expressed genes (Figure S5). Mutations and/or over-expression of
various transporters, especially transporters of the ABC superfamily,
can confer drug resistance in organisms from bacteria to human
cancer cell lines [33,34]. Changes in PfCRT may affect parasite
transport ability; and alteration in the activities of other transporters
may be necessary for the parasite survival.
Genes Expressed in Opposite Direction Between 106/1
76I
and 106/1
76I-352K
Because the two mutant parasites respond inversely to CQ and
QN (106/1
76I is resistant to CQ, but sensitive to QN; 106/1
76I-352K
is sensitive to CQ, but resistant to QN), we investigated if there were
genes associated with the changes in drug responses. Surprisingly,
therewasnogenethatwassignificantly(FDR=0.01)up-regulatedin
one parasite but down-regulated in the other. PFI0115c was
significantly expressed in reciprocal directions in the two mutants
if the cut-off FDR was lowered to 0.05. PFI0115c encodes a protein
kinase with 3.7 fold increased expression in 106/1
76I,b u t1 . 5f o l d
down in 106/1
76I-352K. It is not clear what role this gene plays,
particularly in response to CQ. The result supported the conclusion
that opposite responses to CQ and QN in the two parasites were
mainly due to mutations in PfCRT [5].
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76I and 106/1
76I-352K parasites
Gene name 106/1
K76 106/1
76I 106/1
76I-352K Annotation Signal TM
PFE0080c 0.99 7.01 40.13 rhoptry protein 2, RAP2 1–21 0
PF14_0102 1.00 8.02 32.97 rhoptry protein 1, RAP1 1–21 0
PFE0075c 0.98 4.95 28.18 rhoptry protein 3, RAP3 1–22 0
PFI0270w 0.99 5.47 20.53 intracellular trafficking 20–37 3
PFB0345c 1.00 5.75 18.11 cysteine protease 1–25 0
PFE0395c 0.99 6.04 14.23 hypothetical 1–21 1
MAL13P1.49 1.00 1.80 12.56 hypothetical 1–24 2
PFI0265c 1.00 4.44 11.76 rhoptry protein, RhopH3 1–24 0
PFE1130w 1.00 1.99 11.54 hypothetical 1–28 8
PFI1475w 1.00 2.43 7.82 MSP1 1–19 1
PFI1685w 0.99 3.62 7.62 cAMP-dependent kinase 0 0
PFL1385c 1.00 4.66 6.97 MSP9 1–23 0
PFL0260c 1.00 2.29 6.89 signal transducer 0 0
PF11_0373 1.00 1.36 6.81 cell cycle 1–18 0
PFE0340c 1.00 2.74 6.78 intracellular trafficking 0 6
PFE0895c 1.00 2.97 6.73 transcription regulator 0 0
PF11_0344 1.00 3.71 6.42 AMA1 1–24 1
PFB0340c 1.00 4.94 5.93 cysteine protease 0 0
PFD0240c 1.00 3.29 5.62 hypothetical 1–20 0
PFE0785c 1.00 2.44 5.29 drug/metabolite transporter 0 10
MAL13P1.130 1.00 2.40 4.75 hypothetical 0 6
PFB0845w 1.00 1.69 3.46 hypothetical 0 5
PFL1105c 1.00 1.48 3.13 hypothetical 0 1
MAL7P1.39 1.00 0.62 3.07 hypothetical 0 0
PFF0615c 1.00 1.28 3.07 protein pf12 precursor 1–25 1
MAL7P1.82 1.00 1.47 2.80 signal transducer 23–45 19
PF11_0066 1.00 1.50 2.74 caltractin/Ca2
+-binding 0 1
PFF0170w 1.00 1.59 2.73 Ca2
+/H
+ antiporter VCX1 0 11
PFL1090w 1.00 1.76 2.71 vesicular transport 0 0
PFB0515w 1.00 0.93 2.59 oligosaccharide biosynthesis 1–29 4
PF11_0370 1.00 1.23 2.59 lipid transport 0 4
PFF0335c 1.00 1.47 2.49 hypothetical 1–20 0
PFL1080c 1.00 1.30 2.44 ATPase, PP-loop superfamily 0 0
PFF1180w 1.00 1.25 2.02 cell cycle control 0 0
PFE1115c 1.00 0.30 0.52 methyltransferase 0 0
PFL0700w 1.00 0.41 0.50 hypothetical 1–25 1
PFF0105w 1.00 0.64 0.47 MYND finger domain protein 0 0
PFF1430c 1.00 0.61 0.42 transport_amino acid 0 9
PF13_0219 1.00 0.55 0.38 hypothetical 0 0
PF14_0150 1.00 0.46 0.35 RNA polymerase 0 0
PF11_0265 1.00 0.52 0.26 vesicular transport 0 0
PF10_0016* 0.99 0.01 0.01 lipid transport 0 0
PF10_0019* 1.00 0.01 0.01 membrane protein 1–29 2
PF10_0020* 1.00 0.01 0.01 lipid transport 0 0
PF10_0021* 0.99 0.01 0.01 PHIST domain family 1–21 1
Values for 106/1
76I and 106/1
76I-352K represent significant fold changes (ANOVA; FDR,0.001) relative to 106/1
K76 without CQ treatment. Fold change values represent
means from three biological replicates. Signal, gene products with predicted signal peptide; TM, gene products with predicted transmembrane domains.
* indicates
deleted genes.
doi:10.1371/journal.pone.0002484.t001
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To verify the expression changes seen in microarray hybridiza-
tion, we used real-time RT-PCR to corroborate expression levels of
selected genes. Primer sets were designed for each of 27 selected
genes that were expressed at various levels among three parasites.
Results showed that mRNA levels from real time RT-PCR
correlated well with those from microarray (Figure 3). Three deleted
genes (PF10_0016, PF10_0019, PF10_0020) showed almost no
detectable signal in real-time PCR results. Pearson correlation
coefficients of microarray expression and real-time RT-PCR data
were 0.89 and 0.97 for 106/1
76I and 106/1
76I-352K, respectively
(excluding those deleted genes). PfVP2 (PFL1700c) had similarly
increased expression levels in both CQ-treated and non-CQ-treated
samples when estimated using real time RT-PCR. However, this
gene was only listed in Table 2 with CQ treatment because it had
CV .30% in non-CQ-treated samples and was filtered out during
data preprocessing for the non-CQ-treated samples.
Gene Deletion on Chromosome 10
Hybridization of genomic DNA of the parasites to the same
expressional array chip confirmed the deletion of 4 genes (Table 1)
and an additional 6 genes (PF10_0011 to PF10_0025, chromo-
somal position 60068 to 108663) at the beginning of chromosome
10 as suggested in expression analyses (Figure 4 and Table S1).
Actually, this region includes a total of 15 predicted genes.
However, three of them (all hypothetical proteins) were not
available on the chip. Among the genes deleted were genes
encoding lipid transporters (PF10_0015 and PF10_0016), early
transcribed membrane protein (PF10_0019), surface membrane
proteins such as PfEMP1, and antigen PF70 (Table S1). These
gene deletions were also confirmed using real time PCR (data not
shown). Whether these genes play a role in parasite response to
drugs will require further investigation.
Parasite Growth and Invasion Rates
Many of the differentially expressed genes were putatively
related to cell-cycle/growth or invasion. Therefore we investigated
whether expression changes in these genes could affect parasite
growthorinvasioninculture.Wecomparedthegrowthandinvasion
rates between the three parasites with the same starting parasitemia
(2%) and haematocrit (2%). 106/1
K76 and 106/1
76I-352K had very
similar growth rates; but 106/1
76I growth rate was slightly lower
(not significant) than the other two parasite lines (Figure 5).
Lack of a significant decline in growth rates of drug-selected
mutants is consistent with compensatory changes in the mutant
parasites such as altered regulation of growth-associated genes,
perhaps in response to deleterious effects of changes in pfcrt.
The pfmdr1 CN Variation, Expression Levels, and the
Relationship to Drug Response
In addition to gene deletion on chromosome 10 and significant
changes in expression of the genes listed in Table 1 and Table 2,
changes in pfmdr1 expression in the two mutant parasites (2-fold
Table 2. Genes significantly up- or down regulated in 106/1
76I and 106/1
76I-352K parasites with CQ treatment
Gene name 106/1
K76 106/1
76I 106/1
76I-352K Annotation Signal TM
PFE0080c 1.00 7.80 35.48 rhoptry protein 2 1–21 0
PFE0075c 0.92 8.65 33.77 rhoptry protein 3 1–22 0
PF14_0102 1.01 10.41 33.30 rhoptry protein 1 1–21 0
PFL1700c 0.97 4.05 10.15 V-type H
+ pyrophosphatase 0 16
PFB0340c 0.99 4.90 6.20 cysteine protease 0 0
PFD0660w 1.00 1.49 2.12 phosphoglycerate mutase 0 1
PFC0080c 1.00 0.47 0.39 cell cycle control 20–38 2
PF10_0016 1.07* 0.02 0.02 lipid transport 0 0
PF10_0019 1.01* 0.01 0.01 membrane protein 1–29 2
PF10_0020 1.00* 0.01 0.01 lipid transport 1–21 1
PF10_0021 0.98* 0.01 0.01 hypothetical protein 0 0
Values for 106/1
76I and 106/1
76I-352K represent significant fold changes (ANOVA; FDR,0.001) relative to 106/1
K76 with CQ treatment. Fold change values represent
means from three biological replicates. Signal, gene products with predicted signal peptide; TM, gene products with predicted transmembrane domains.
* indicates
deleted genes.
doi:10.1371/journal.pone.0002484.t002
Figure 2. Gene Ontology (GO) biological processes enrichment
levels among 2-fold differentially expressed genes in response
to CQ treatment in both mutants. The enrichment levels (enrichment
score) weremeasuredby2log(Pvalueofeachterm)fromtheFisherexact
test (see Methods). Red color indicates higher enrichment level. The
analysesshowedCQ-treatedsampleswerehighlyenrichedinglyceroland
polyol metabolic processes in both mutant parasites.
doi:10.1371/journal.pone.0002484.g002
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76I) were also detected. Changes in pfmdr1
CN were associated with parasite responses to MQ and other drugs
[20]. If we normalized pfmdr1 CN to that of 106/1
76I,1 0 6 / 1
76I-352K
and 106/1
K76 had 2–5 copies, depending on methods used to
estimate CN (Table 3). A higher CN of the pfmdr1 gene and higher
level of expression also appeared to correlate with higher IC50 to
MQ and ART (Table 3). However, when we tested additional field
isolates from Asia, the correlation disappeared (Table S2).
Discussion
Although PfCRT has been shown to play to a key role in CQR,
the molecular mechanism of CQ action and CQR has not been
resolved completely. Parasites resistant to CQ (and having
mutations in PfCRT) accumulate less CQ, either due to a process
of active energy-dependent CQ efflux [35,36,37] or passive efflux
of diprotic CQ [38,39,40], a process that remains to be
determined [9]. Importantly, the endogenous function and
substrate(s) of PfCRT remain unknown. The inability to create
pfcrt knockouts, its multi-transmembrane structure and cellular
location suggest that PfCRT is involved in the transport of critical
substrates into/out of the parasite FV. Several lines of experi-
mental evidence indicated that mutations in PfCRT could affect
FV membrane transport or pH balance; but how it exerts this
activity is still being debated. Although controversial, parasites
resistant to CQ were reported to have a lower pH in their FV than
those in parasites with wild type PfCRT [41]. Therefore, in
Figure 3. Real-time RT-PCR confirming some differentially
expressed genes detected using microarray. Genes differentially
expressed at various levels were selected for PCR verification. For the
majority of the genes tested, the copy numbers of mRNA transcripts
detected using real time RT-PCR correlated well with those of
microarray (R
2 were 0.8909 for 106/1
76I and 0.9669 for 106/1
76I-352K).
Squares represent 106/1
76I; circles represent 106/1
76I-352K.
doi:10.1371/journal.pone.0002484.g003
Figure 4. Gene deletions detected using DNA hybridization. Genomic DNA from 106/1
K76, 106/1
76I, and 106/1
76I-352K were hybridized to the
same microarray. Hybridization signals of 106/1
76I-352K (A) or 106/1
76I (B) were subtracted from those of 106/1
K76 after normalization and were plotted
along each chromosome. X-axis represents the P. falciparum 14 chromosomes numbered 1 to 14; and Y-axes are the log ratio of signals from 106/
1
76I-352K or 106/1
76I over that of 106/1
K76, respectively. Note deletions of 10 genes at one end of chromosome 10 in both mutant parasites (arrows).
doi:10.1371/journal.pone.0002484.g004
Figure 5. Parasite growth rates measured from in vitro culture.
Parasitemias were obtained by daily counting of parasites from Geimsa-
stained thin smears. Parasite cultures were started at 2% parasitemia
and 2% haematocrit. Error bars are standard errors from 4–6 repeated
measurements. The three parasite lines had similar growth rates in
culture.
doi:10.1371/journal.pone.0002484.g005
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functions of PfCRT may include maintaining pH balance in the
FV or modulate the pH gradient across the FV membrane [42].
Heterologous expression in yeast (Pichia pastoris) and Xenopus laevis
oocytes suggested that PfCRT had transporter activity that might
affect membrane potential. Studies in P. pastoris revealed an
increased proton (H
+) gradient across the vesicular membrane
with reduced pH inside, which was thought to be due to either the
effect of PfCRT on chloride (Cl
2) transport or ATPase activity
[43]. Expression of PfCRT in X. laevis oocytes led to a reduced
intracellular membrane potential and an alkaline pH relative to
controls which were attributed to the activation of a non-selective
cation transporter (Gcat) and an endogenous Na
+-H
+ exchanger
[44]. However, expression of PfCRT in Dictyostelium discoideum
resulted in only a small reduction in pH and significantly reduced
verapamil-reversible intravesicular CQ accumulation in the
mutant K76T lines relative to the control [37], suggesting a
PfCRT-mediated energy-dependent efflux mechanism. Another
possible role for PfCRT is the transport out the FV of amino acids
resulting from hemoglobin digestion. Mutations in PfCRT may
therefore affect these physiological processes.
This study identifies several putative transporters that might
play a role in CQR or in adaptation to changes in PfCRT in P.
falciparum. PfVP2, Ca2
+/H
+ antiporter VCX1, the putative drug
transporter PFE0785c, and ATPase/synthase (PF11_0412 and
PFC0840w) may represent molecules that the mutant parasites
mobilize in response to the amino acid 76 mutation in PfCRT.
Increased transcription of the gene encoding PfVP2 was seen in
PfCRT mutant parasites with and without CQ pressure based on
real-time RT-PCR. Although we did not see statistically significant
changes in gene transcript levels between CQ-treated and non-
treated, our GO functional enrichment analysis showed that CQ-
treated mutants have significant enrichment in glycerol and polyol
metabolic processes in both mutant parasites, and enrichment of
iron/cation transport activities in the double mutant. This
indicates that short-term CQ treatment may not significantly alter
the expression of individual genes, but may assert small effects on
groups of genes that together can cause a significant change at
biological pathway/process levels.
One interesting gene with up-regulated transcripts in both pfcrt
mutants was PFE0785c. This gene has 10 transmembrane
domains and was recently annotated to encode a putative drug/
metabolite transporter. PfCRT also has 10 transmembrane
domains and was predicted to encode a putative drug/metabolite
transporter [11]. The similarity between the two genes raises an
interesting question on whether the two genes have similar
functions in drug/metabolite transport. Three potential single
nucleotide polymorphisms (SNPs) in coding regions and two in
UTR regions of PFE0785c have been identified in PlasmoDB.
Further investigation on the SNPs and parasite drug responses to
different drugs may provide insight information on the function of
this gene.
Two V type H
+ pyrophosphatases (PfVP1 and PfVP2) have
been described in P. falciparum, which constitute a novel class of H
+
pump found in plants and some protozoa [32,45]. The V-type H
+
pyrophosphatases were found to be located on parasite plasma and
vacuolar membranes, although the PfVP2 was expressed at a low
level and could not be distinguished from PfVP1 [32,45]. In
experiments using inside-out plasma membrane vesicles, vesicles
from yeast membrane carrying mutant PfCRT (Dd2 type) were
found to have elevated ATPase and H
+ transporting activities [43].
Because PfCRT does not have a recognizable ATPase domain,
one of the potential explanations of this observation was that the
mutant PfCRT might directly interact with H
+-ATPase and
become more efficient in stimulating both hydrolysis of ATP and
H
+ pumping in the presence of high symmetrical [Cl
2] [43]. The
up-regulation of the PfVP2 could be a response to the alteration in
the ability of PfCRT to regulate FV pH. Nonetheless, these
molecules appear to be present at the same location (FV
membrane) and may work together in regulating the compart-
mental pH, which is closely related to accumulation of weak base
drugs such as CQ. These results suggest that pfcrt may be indirectly
involved in maintaining H
+ balance in the parasite FV, consistent
with previous reports of lower pH in CQR parasites with mutant
pfcrt [41]. Further investigation of the roles of PfVP2 and the gene
encoding Ca
2+/H
+ antiporter in maintaining pH in the parasite
and in CQR may lead to a better understanding of CQR in P.
falciparum and the biological functions of PfCRT.
Another interesting observation was the change in pfmdr1 CN
accompanying the CQ-selected pfcrt mutations. pfmdr1 CN
decreased from 5 copies to 1 copy after CQ selection of 76I
(from the original 76K) in PfCRT; and increased to ,4 copies
after QN selection (real time PCR data). mRNA levels were
similarly changed in response to pfcrt mutations and drug selection
(Table 3) and support the argument CN changes influence pfmdr1
expression in response to CQ selection and/or mutations in
PfCRT. Increased CN of pfmdr1 have also been associated with
increased IC50 values to MQ both in field isolates and laboratory-
selected parasites [20,46]. Interestingly, MQ-selected parasites also
showed an inverse relationship between CQ response levels and
increased pfmdr1 gene CN [46]. The proteins encoded by pfcrt and
pfmdr1 are located at the FV membrane [3,47], suggesting a
contribution to the FV function and potential direct interactions.
Because our pfcrt mutants were selected using lethal doses of CQ or
QN to provoke the emergence of pre-existing mutants, it is
possible that pfmdr1 CN variants were also present before drug
Table 3. Pfmdr1 copy number (CN) estimates, mRNA expression levels, and parasite responses to four different drugs
Parasites CN_RTPCR CN_Array Expr_RRPCR Expr_Array CQ MQ QN ART
106/1
K76 5.0 1.7* 3.3 2.5 11.160.2 5.060.3 84.963.5 11.161.2
106/1
76I-352K 3.5 2.0 1.7 2.0 9.160.9 4.260.5 93.164.9 9.361.0
106/1
76I 1.0 1.0 1.0 1.0 223.8615.6 2.760.2 13.062.1 7.561.9
CN and mRNA levels were normalized to those of 106/1
76I (the lowest values). CN were averages of two different primer pairs using three different single copy genes
(60S rRNA, b-tubulin, and PfEBA-175) as internal controls in PCR. Expression values from microarray were also averages of many separate experiments described int h e
text. Data for CQ (chloroquine), MQ (mefloquine), QN (quinine) and ART (artemisinin) represent IC50 values (nM) determined from 4–6 biological replicates. CN_RTPCR,
relative CN determined using real time-PCR; CN_array, relative CN determined using microarray; Expr_RRPCR, relative mRNA level determined using real time RT-PCR;
Expr_array, relative mRNA level determined using microarray.
*The CN was estimated to be 3 using a printed oligonucleotide array (data not shown).
doi:10.1371/journal.pone.0002484.t003
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specific pfcrt alleles. Substitutions in amino acids of PfMDR1
(Pgh1) could be another way that the parasite compensate for the
pfcrt mutations as certain pfmdr1 alleles have been shown to be
closely linked to different mutant pfcrt alleles [22,23,48]; however,
no substitution in the pfdmr1 was observed among the two mutant
parasites [5]. Increased pfmdr1 CN also appeared to have higher
mRNA expression levels and slightly higher IC50 for MQ/ART
among the three parasite lines (Table 3), which were not selected
with MQ or ART. The results also suggest that the observed
association of higher MQ IC50 and pfmdr1 CN in field parasites
may be a combined result from selection of multiple drugs such
CQ, QN, and MQ. However, pfmdr1 CN change is unlikely to be
the major determinant causing changes in IC50 for the drugs we
tested as there were no clear correlation between pfmdr1 CN and
CQ IC50 (Table S2). Given the opposite selection pressure of CQ
and MQ/ART on pfmdr1, addition of CQ to ART treatment may
improve the efficacy of ART, although CQ alone is not effective in
many parts of the world.
Mutations in PfCRT may affect the parasite growth or survival.
There is evidence showing that parasites with mutations in PfCRT
may have reduced ability to compete with wild type parasites. In
some endemic regions of Africa and Asia, cessation of CQ use has
resulted in the return of parasites with wild type PfCRT among
parasite populations highly resistant to CQ [14,15,49]. Additionally,
most of the field PfCRT mutant parasites carry multiple amino acid
substitutions. Simultaneous changes of multiple positions in PfCRT
suggest that the substitution at amino acid position 76 may also
require changes at other positions in the molecule in order to
maintain cellular homeostasis [1,8], although such changes may not
restorefullactivityofPfCRT.The requirement ofothersubstitutions
to compensate for changes at amino acid position 76 can explain
why PfCRT 76 mutations could only be selected from parasite 106/
1
K76 in in vitro culture that has several pre-existing mutations in the
molecule, but not from other wild type parasites [3,5]. The majority
of the individual changes in PfCRT probably result in a fitness cost
for the parasite, explaining why only one or two amino acid changes
in PfCRT have not been observed in laboratories or in the field
populations. Requirement of multiple changes simultaneously in
PfCRT can also explain relatively rare events of founder mutations
for CQR [50]. Therefore, compensatory changes in the genetic
background of the key position 76 PfCRT CQR mutation could
occur at several levels. The first one is changes within PfCRT itself.
The substitution at position 76 is critical for conferring CQR, and
other changes that vary with independent evolutionary origins of
CQR can be directly involved in the CQR mechanism or can be
simply compensating biological function of the protein. Compensa-
tory changes within PfCRT may not fully restore the biological
functions of the protein, thereby requiring further changes in other
parts of the genome, presumably influencing expression or function
of genes whose functional products relate to the fitness impacts of the
natural biology of PfCRT. Notably, the expressional changes we
report are limited to potential compensatory changes in other genes
in response to substitution of 76I or 325K in pfcrt.
Compensatory changes for drug resistant mutations have been
widely reported in microorganisms. One example is the compen-
satory adaptation to the loss of fitness associated with changes in
elongation factor G conferring resistance to fusidic acid in
Staphylococcus aureus [13]. In our study, many genes highly up-
regulated in RNA expression were those involved in parasite
invasion (rhoptry proteins and merozoite surface proteins) and
growth (proteins in cell cycle, transcription and translation
regulators, and proteases). In malaria parasites, cysteine proteases
have been shown to play a role in merozoite release from the
erythrocyte [51]. Our results showed that the two pfcrt mutants had
significant increase in transcription levels of many genes that were
related to parasite invasion and growth, although some of the
responses might be non-specific to the two pfcrt mutations.
However, the two PfCRT mutants had similar growth and
invasion rates as the parent line 106/1
K76 in regular erythrocyte
culture (Fig. 5). One possibility is that despite high transcription
levels, protein expression of these genes may change minimally.
Other possibilities are redundancy of parasite mechanisms related
to growth and invasion, or the changes in expression of these genes
were responses to deleterious impacts on growth.
The genes deleted on chromosome 10 included four genes
encoding antigen/parasite membrane (e.g. PfEMP1, PF70), two
encoding acyl CoA binding protein or lipid transporters, two genes
encoding alpha/beta hydrolases, the rest two genes was recently
assigned to Plasmodium helical interspersed subtelomeric (PHIST)
family and contain a PEXEL trafficking motif. Interestingly, in the
middle of those deleted genes, PF10_0014 did not show much
difference in hybridization signals among these 3 parasites. The
functional effects of these deletions on parasite growth and
response to CQ or PfCRT mutations are unknown.
In summary, mutations in PfCRT caused limited changes in P.
falciparum global RNA gene expression with or without short-term
CQ pressure, even though parasite sensitivity to CQ and QN were
dramatically altered. Therefore, the changes in CQ and QN
resistance phenotypes in the mutants could be largely attributed to
the key mutation(s) in PfCRT. However, mutations in PfCRT,
particularly at amino acid position 76, could affect normal cellular
functions, possibly in maintaining FV pH. The loss (or reduction)
of function in PfCRT could be compensated through increased
expression of some other transporters such as PfVP2 and/or
changes in CN of pfmdr1. Other compensatory changes not
detected by this analysis might have also occurred; and the
changes identified in this study will require further investigations
that may provide insights into the endogenous function of PfCRT
and its role in CQR in P. falciparum.
Materials and Methods
P. falciparum Parasites and in vitro Culture
Parasites were cultured in vitro according to the methods of Trager
and Jensen [52]. Briefly, parasites were maintained in RPMI 1640
medium containing 5% human O
+ erythrocytes (5% haematocrit),
0.5% Albumax (GIBCO, Life Technologies, Grand Island, NY),
24 mM sodium bicarbonate and 10 mg/ml gentamycin at 37uC with
5% CO2,5 %O 2,a n d9 0 %N 2. P. falciparum isolate 106/1
K76 and its
two isogenic PfCRT mutants 106
76I and 106
76I-352K were used in
this study [5]. Parasite 106/1
K76 has six mutations found typically in
Southeast Asian CQR parasite (compared with 3D7 and other CQS
wild type parasites), except a key mutation at PfCRT 76 position [1].
106/1
K76 issensitivetoCQ(IC50=34nM),butrelativelyresistantto
QN (IC50=205 nM). The mutant parasite 106
76I was derived from
106/1
K76 using a lethal dose of CQ (100 nM) that selects for a pre-
existing parasite with mutation at 76 position. 106
76I is CQR
(IC50=589 nM) but exceptionally sensitive to QN (IC50=16nM)
[3]. 106/1
76I-352K was derived from 106/1
76I using a lethal dose of
QN (100 nM); and the parasite reverted to CQS (IC50=26 nM) and
became more resistant to QN (IC50=240 nM) [5]. The identity of
each parasite clone was confirmed using microsatellite genotyping
and sequencing the entire pfcrt open reading frame [53].
RNA and DNA Extraction
Parasites were synchronized in three successive steps: 1) 5%
sorbitol treatment of ring stage, 2) Percoll-sorbitol (80%:40%)
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5% sorbitol treatment of ring after another 10–12 h [54,55]. Total
RNA was isolated 24 h after the last step of synchronization with
parasites (,5%) mostly at trophozoite stage in 150 ml flasks (Figure
S6) using Trizol extraction protocol according to the manufacturer’s
instruction (Invitrogen, Carlsbad, CA). We used trophozoite because
thisisthestagethatisactivelygrowingandissensitivetomanydrugs,
including CQ [56]. All RNA samples for each parasite and each
treatment were prepared at different times (three biological
replicates). The quantity and quality of the RNA samples were
estimated using spectrophotometry, agarose gel electrophoresis, and
Agilent 2100 Bioanalyzer (Foster City, CA). Genomic DNA was
extracted from saponin-lysed parasite pellets using Wizard Genomic
DNA Purification Kit (Promega, Madison, WI).
CQ Treatment
For testing parasite expressional changes in response to short-
term low dosage of CQ, we cultured parasites with or without CQ
for 3 h before RNA extraction based on previously established
IC50 levels of each parasite [5]. The CQ (chloroquine diphosphate
salt, Sigma-Aldrich, St. Louis, MO) concentrations used were half
of the IC50 value for each parasite: 106/1
K76, 15 nM; 106/1
76I,
295 nM; 106/1
76I-352K, 10 nM [4].
Invasion and Growth Assays
Schizonts were purified using percol/sorbitol gradient
(80%:40%) and diluted to 2% initial parasitemia in 2%
haematocrit. For invasion rate, the numbers of ring stage parasites
from 10–20 microscope fields (,2000 RBCs) were counted as
described [57] after 18–20 h of culture. The parasites were also
stained with EtBr and counted using a flow cytometry after 48 h of
culture. Growth rates were monitored everyday after synchroni-
zation by counting the parasitemia using the above two methods.
Culture media were changed everyday, and the assays were
repeated 4–6 times on all parasites.
RNA and DNA Labeling and Hybridization
The Johns Hopkins Plasmodium/Anopheles Expression Array
(http://www.affymetrix.com/products/arrays/specific/plasmodium.
affx) that has 5,407 probsets covering 4,700 predicted P. falciparum
genes were purchased from Affymetrix (Santa Clara, CA). The
array contained short oligonucleotides (25-mer) synthesized in situ
on a glass slide, with each predicted coding region having multiple
probes (11 probe pairs per gene). RNA labeling (5 mg total RNA)
and hybridization were performed following Affymetrix standard
protocols for eukaryotes using One Cycle Target Labeling and
Control Reagent Kit. Genomic DNA was also fragmented to an
average size of 50–150 bp with DNase I and subsequently end-
labeled using terminal deoxynucleotidyl transferase (TdT) and a
biotin labeling kit (Affymetrix Mapping 250K reagent kit). Biotin-
labeled cRNA and cDNA were hybridized to the chip at 45uC for
16 h with constant rotation at 60 RPM. Affymetrix 20X
hybridization control was used to make the hybridization cocktail.
Microarray Signal Scanning and Data Analysis
Hybridized chips were washed and stained following the
company’s EukGE-WS2v5 protocol. The chips were scanned
at 570 nm emission wavelength using Affymetrix scanner
3000. Image CEL files were processed and normalized using the
Robust Multi-array Analysis with correction for GC content of the
oligos (GC-RMA) [58], and the processed data were imported into
GeneSpring (v7.2, Agilent Technologies) for further data filtering,
normalization, and analyses. To maximize the proportion of high
quality transcripts, data were filtered using a coefficient of variance
(CV) cut-off value of 30%. Signal from each gene was normalized
to the means of three 106/1
K76 replicates (non CQ-treated).
Default settings in GeneSpring were used for hierarchical
clustering and principal component analysis (PCA) for all the
samples. Differentially expressed genes were identified based on 2-
fold up- or down changes and significance at FDR of 0.001
(Benjamini and Hochberg FDR multiple test correction) using
analysis of variance (ANOVA). Functional annotation of P.
falciparum genes was based on those in PlasmoDB and additional
Blast searches of various databases. All raw data and minimal
information about a microarray (‘‘MIAME’’) checklist were
submitted to NCBI Gene Expression Ominibus (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE10022) and Plas-
moDB (http://www.plasmodb.org/plasmo/home.jsp).
Functional Enrichment Analysis Using Gene Ontology
The functional enrichment analysis was performed using WPS
software [59]. Genes associated with biological processes,
molecular functions and cellular components were derived from
Gene Ontology (GO) Consortium (http://www.geneontology.org)
and were used for functional enrichment analysis. Briefly, the one-
sided Fisher’s exact test based on 262 contingency tables (whether
a gene is in a given list or not vs. whether this gene is associated
with a GO term or not) was used to determine which GO term
had a statistically significant enrichment within differentially
expressed genes. The permutated P value or FDR for pathway
enrichment was calculated with a permutation number of 300.
Results of multiple gene lists from the Fisher exact test were
compiled and displayed in color-coded heat maps to reveal the
patterns of significantly altered biological processes and pathways.
The color-coding of the heat maps is based on the enrichment
score of genes in a pathway (2Log (P value) of each term) with red
color indicating a higher level of enrichment.
Real Time Quantitative RT-PCR
Real time RT-PCR was performed to verify expressional levels
of selected genes; and real time PCR was used to determine CN of
pfmdr1 in the parasites. First strand cDNA synthesis was performed
using Superscript First Strand Synthesis System kit (Invitrogen)
and oligo-dT and random hexamers as primers. Quantitative real-
time PCR was performed in an iCycler iQ
TM multicolor real-time
detection system (Bio-Rad) using the iQ SYBR Green Supermix
(Bio-Rad).
Primers for real-time PCR (Table S3) were designed to produce
amplicons of 80–150 bp after blasting against the whole genome to
ensure specificity. A total of 27 genes with different levels of
expression detected using microarray were selected for real-time
PCR verification using the same RNA purified for microarray
hybridizations. For estimating the CN of pfmdr1, we used two sets
of primers. One pair of primers was the same as those described
[20]. The sequences of second pair of primers were: forward 59-
ACTATTGCCCACAGAATTGC-39 and reverse 59-CCATCT-
TGTGCTGATAATAATTC-39. The quantity of cDNA/DNA
was first calibrated using serial-diluted plasmid DNA, then
normalized using internal control genes encoding 60S ribosomal
subunit protein L18 (MAL13P1.209) for RNA, and b-tubulin
(PF10-0084) and PfEBA175 (MAL7P1.176) for gDNA, and finally
expressed as relative levels to the parent line 106/1
K76 in each set
of experiment. The reactions were carried out according to
manufacturer’s instructions with the following cycling program:
5 min at 95uC for initial denaturation; 95uC for 30 s, 50uC for
30 s, 60uC for 30 s for 45 cycles; and a final extension at 55uC for
1 min.
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Drug assays were performed using SYBR Green I method
modified from a procedure described previously [60]. Briefly,
parasites were diluted to 1% parasitemia in 1% haematocrit and
aliquoted (150 ml) into a 96-well plate with wells containing 50 ml
of a serial-diluted drugs or drug-free controls. After incubation at
37uC for 72 h, DNA were released from cultured parasites and
stained with SYBR Green I dye as described. The plate was kept
in dark for 30 min and signals were read in a FluoStar microplate
reader (BMG Labtech, Germany). IC50 values were calculated
using nonlinear regression to yield the drug concentration that kills
50% of the parasites relative to the drug-free controls. Data were
fitted to a sigmoidal dose-response/variable slope equation using
the GraphPad Prism 5.0 software package (San Diego, CA).
Supporting Information
Figure S1 Boxplots of unprocessed log scale probe intensities.
Samples in red were from 106/1K76; in blue were from 106/176I;
and in yellow were from 106/176I-352K. Among the six samples,
three were treated with CQ and other three were untreated
Found at: doi:10.1371/journal.pone.0002484.s001 (0.08 MB TIF)
Figure S2 Distribution of probeset intensity. Each line repre-
sents one of the 18 microarray chips tested. Plotted on the Y-axis is
mean intensity by probeset position. Intensities have been shifted
from original data for better viewing (due to overlapping lines), but
slopes are unchanged.
Found at: doi:10.1371/journal.pone.0002484.s002 (0.11 MB TIF)
Figure S3 MA-plots showing distribution of normalized data.
Each comparison consists of averaged data from six chips
representing each of the three parasites. M is the log-ratio of the
expression intensities between two parasites, whereas A is the
mean log-expression intensities between two parasites. The red
lines are the LOESS smoother/regression lines.
Found at: doi:10.1371/journal.pone.0002484.s003 (0.15 MB TIF)
Figure S4 Principal component analysis of whole genome
expression data (3,356 probesets/genes) from 18 hybridizations.
The first two principal components account for 82.8% and 7.7%
of the variance in the data sets, respectively. Each dot or circle
represents one hybridization. Dots in red are samples treated with
chloroquine.
Found at: doi:10.1371/journal.pone.0002484.s004 (0.21 MB TIF)
Figure S5 Up-regulated expression of genes associated with
iron/cation transport in the PfCRT mutants. Each segment of the
gene bars represents expressional levels (as color-coded) of the
genes in each parasite (represented as a segment); and the levels of
expression in fold changes are as labeled. The percentages under/
above the four segments of the GO term bars (iron and cation
transport) indicate the percentage of annotated genes for the
intended GO term from the corresponding dataset reaching the
color-coded criteria. For example, 12% of the genes belonging to
cation transport were 2-fold up-regulated in the 106/176I-352K
parasite after treated with CQ. The thin lines indicate each of the
two GO terms and their associated genes.
Found at: doi:10.1371/journal.pone.0002484.s005 (0.19 MB TIF)
Figure S6 Micrograph showing synchronized trophozoites prior
to RNA extraction. Parasites were stained with 1% Giemsa. A,
106/1K76; B, 106/176I; C, 106/176I-352K
Found at: doi:10.1371/journal.pone.0002484.s006 (7.91 MB TIF)
Table S1 Genes deleted in 106/176I or 106/176I-352K
parasites
Found at: doi:10.1371/journal.pone.0002484.s007 (0.01 MBXLS)
Table S2 pfmdr1 copy numbers and parasite responses (IC50,
nM) to antimalarial drugs. CN was estimated using real time PCR
described in the text. The additional parasite isolates were
described previously [21]. CN, copy number; CQ, chloroquine;
MQ, mefloquine; QN, quinine, and ART, artemisinin. IC50
values were determined using 4–6 independent replicates. Copy
numbers were adjusted to one copy for 106/176I.
Found at: doi:10.1371/journal.pone.0002484.s008 (0.04 MB
DOC)
Table S3 Primer sequences used in real time PCR
Found at: doi:10.1371/journal.pone.0002484.s009 (0.02 MB
DOC)
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